πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 113 of 173

  1. US 8378109

    Labeled ALPHA4BETA2 ligands and methods therefor

    Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 8378084

    Fusion molecule based on novel TAA variant

    Expires Mon Feb 14 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8372380

    In vivo imaging of sulfotransferases

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8372826

    Estriol therapy for multiple sclerosis and other autoimmune diseases

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8372848

    Melanin-concentrating hormone receptor antagonists and methods of use

    Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 8367052

    Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 8367401

    Replication competent hepatitis C virus and methods of use

    Expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 8361471

    Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 8362277

    Pro-neurogenic compounds

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 8361756

    Bifidobacterial gene sequences and their use

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8361768

    Heat resistant bioactive composition

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8361733

    Methods of identifying modulators of a cold-and-menthol-sensitive receptor (CMR1) and recombinant cells for use thereof

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8361508

    Endocytotic particles

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8361982

    Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8361459

    Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells

    Expires Mon Jan 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8357374

    Conjugates of synthetic TLR agonists and uses therefor

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8357379

    High concentration baclofen preparations

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8357656

    Natriuretic peptide receptor-C agonists

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8357365

    Granulysin peptides and methods of use thereof

    Expires Mon Jan 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8354450

    Creatine oral supplementation using creatine hydrochloride salt

    Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8354538

    Small-molecule inhibitors of the androgen receptor

    Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8354240

    VMP-like sequences of pathogenic Borrelia

    Expires Mon Jan 10 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8350042

    Antiviral compounds for the treatment of HCV infection

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8349353

    Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8348921

    Gels with predetermined conductivity used in electroporation of tissue

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 8349910

    Aldehyde tags, uses thereof in site-specific protein modification

    Expires Mon Jan 03 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 8343931

    Methods of inhibiting photoreceptor apoptosis

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 8343481

    Method of preparing lung alveolar epithelial type II cells derived from embryonic stem cells

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 8343539

    Compounds that bind Ξ±5Ξ²1 integrin and methods of use

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 8343506

    Chimeric chikungunya virus and uses thereof

    Expires Mon Dec 27 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8337830

    Yeast-based vaccines as immunotherapy

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 8338398

    Composition and method of treating hearing loss

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8338397

    Composition and method of treating side effects from antibiotic treatment

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8338366

    Bioactive FUS1 peptides and nanoparticle-polypeptide complexes

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8337866

    Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8334259

    Method of treating endothelial dysfunction comprising administration of a thrombin peptide derivative

    Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8334239

    High affinity VEGF-receptor antagonists

    Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8333959

    Ex-vivo application of solid microparticulate therapeutic agents

    Expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8328785

    Use of nanoparticles in the photodynamic treatment of tumors

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8329636

    Carcinoma diagnosis and treatment, based on ODC1 genotype

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8329873

    Bispecific single chain Fv antibody molecules and methods of use thereof

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8329179

    Death domain containing receptor 4 antibodies and methods

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8329745

    Small molecule inhibitors of ghrelin O-acyltransferase

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8329753

    Combination of compounds, or a bifunctional compound, that provides fatty acid metabolism and glycolysis inhibition

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8329141

    Locoregional internal radionuclide ablation of abnormal tissues

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8323962

    Molecules with extended half-lives, compositions and uses thereof

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8324258

    F1F0-ATPase inhibitors and related methods

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8324192

    Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.